Home         Archives         About Us        Submission Guidelines        Editorial Board        Advertising Information         Contact Us

Blazing a Trail Through the Virtual World of ASCO and COVID-19

 

Who could have predicted at last year’s meeting of the American Society of Clinical Oncology (ASCO) that all content for the 2020 sessions would be virtual and only available online? How could that happen? Maybe a pandemic?

     Fast-forward to the surreal world of Covid-19 and the virtual highlights from ASCO. It is astonishing to consider that in contrast to this year, in 2019 there were 42,500 registrants for the ASCO meeting, and nearly 20,000 attendees from the US alone gravitated to this global event. This year, approximately 2215 abstracts were accepted for presentation during this year’s program and more than 3400 additional abstracts were accepted for online publication, according to ASCO.

      Nevertheless, as relentless as the pandemic has been, ASCO meetings fortunately take on a momentum of their own, even when the sessions are virtual. Despite the absence of face-to-face discussion, this year’s agenda did not disappoint in providing data with sharp impact on oncology and implications for managing renal cell carcinoma (RCC). Controversies and trends from previous poster sessions and abstract presentations re-emerged, yielding some new if not “milestone” types of insights. But the devil is in the details, and unpacking information from online posts provides much to review with potential applications.

     If there is scant evidence of dramatic shifts in the paradigm, occasionally seen during previous annual sessions, incremental progress has been sustained on many investigative fronts. continue 

 

Robert A. Figlin, MD

COVID-19 and

Cancer Resources

Click here for Top Abstracts

To view the current issue

as a PDF file, click here

Unpacking the Virtual ASCO20 Sessions:
What Are The Latest Developments in the RCC Toolbox?

 

Senthil Pazhanisamy, PhD

Executive editor, Kidney Cancer Journal      Read

Current Guidelines for Treating Oligometastatic RCC: An Ever-changing Paradigm Integrates New Strategies

 

Alexandra Drakaki, MD, PhD1, Albert J. Chang, MD2, and Allan J. Pantuck, MD, MS, FACS3

 

1Assistant Professor of Medicine (Hematology/Oncology) and Urology, Medical Director of the GU Oncology Program at the Institute of Urologic Oncology at UCLA, Los Angeles, CA

2Associate Professor, Vice Chair of Surgical Services and Brachytherapy, Service Chief, Department of Radiation Oncology,

David Geffen School of Medicine at UCLA and UCLA Institute for Urologic Oncology, Los Angeles, CA

3Professor and Vice Chair for Academic Affairs, Department of Urology, UCLA Institute for Urologic Oncology, Los Angeles, CA    Read

The Current and Evolving Landscape of Immunotherapies for Advanced Renal Cell Carcinoma

 

Allen Jacob, MD1, Jaret Shook2, and Thomas E Hutson, DO, PharmD, FACP3

 

1Texas A&M College of Medicine,  Bryan TX;

2Ohio Northern University College of Pharmacy, Ada, OH and Urologic Oncology Program,

3Texas Oncology, Baylor Sammons Cancer Center, Dallas, TX     Read

 

 

Sequencing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma During the VEGF-TKI and Immunotherapy Era

 

Jun Gong, MD

Department of Medicine

Division of Hematology and Oncology

Cedars-Sinai Medical Center

Los Angeles, California      Read

 

 

Uveal Melanoma and Kidney Cancer:
More Similar than Meets the Eye

 

Nirmish Singla, MD, MSCS

Urology Service, Department of Surgery

Memorial Sloan Kettering Cancer Center

New York, NY      Read

 

 

Newsworthy, late-breaking information from Web-based sources, professional societies, and government agencies

 

KCA accepting applications for investigator awards

HOUSTON—The Kidney Cancer Associations is accepting applications for their Young Investigator Awards (YIAs) through August 5, 2020. Four $75,000 YIAs are available. Recipients will be announced in fall 2020.

    YIAs encourage promising researchers in urology and clinical oncology who are planning to pursue an investigative career in kidney cancer.

    The priority research areas that emerged as a result of the KCA’s Think Tank: Coalition for a Cure, held last fall in conjunction with the 18th International Kidney Cancer Symposium, included cure or durable therapeutic response, improved screening and surveillance, neoadjuvant and adjuvant treatment strategies, and non-clear cell renal cell carcinoma. All grant proposals will be evaluated by an independent panel of reviewers, who are recognized experts in the field. They will conduct a blinded, scored review of all applications received.

    Complete details about the grant application process are available here: https://kidneycancer.submittable.com/submit  All questions regarding the grant application process should be submitted to grants@kidneycancer.org.

 

FDA approves additional pembrolizumab dosing strategy, 400 mg per 6 weeks

The FDA has approved an additional recommended dosage of 400 mg every six weeks (Q6W) for pembrolizumab (Keytruda), the anti-PD-1 therapy, across all adult indications, including monotherapy and combination therapy.                  continue

 

 

Copyright © 2020

ISSN 1933-0863 (PRINT)   

ISSN 1933-0871 (ONLINE)

Follow us on social media.

 

2Ohio Northern University College of Pharmacy, Ada, OH and Urologic Oncology Program,

COVID-19 and

Cancer Resources

The Official Journal of the Kidney Cancer Association

Home     Archives     About Us     Submission Guidelines       Editorial Board      Advertising Information     Contact Us

COVID-19 and

Cancer Resources